Unity Biotechnology
About: Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
Employees: 16
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
1.68% less ownership
Funds ownership: 20.54% [Q3] → 18.86% (-1.68%) [Q4]
3% less funds holding
Funds holding: 38 [Q3] → 37 (-1) [Q4]
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
33% less funds holding in top 10
Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]
39% less capital invested
Capital invested by funds: $5.09M [Q3] → $3.11M (-$1.98M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Chardan Capital Daniil Gataulin 22% 1-year accuracy 11 / 50 met price target | 254%upside $4 | Buy Maintained | 23 Apr 2025 |
HC Wainwright & Co. Matthew Caufield 25% 1-year accuracy 17 / 68 met price target | 254%upside $4 | Buy Reiterated | 23 Apr 2025 |
Financial journalist opinion









